Cargando…

Feedback activation of EGFR/wild-type RAS signaling axis limits KRAS(G12D) inhibitor efficacy in KRAS(G12D)-mutated colorectal cancer

Colorectal cancer (CRC), which shows a high degree of heterogeneity, is the third most deadly cancer worldwide. Mutational activation of KRAS(G12D) occurs in approximately 10–12% of CRC cases, but the susceptibility of KRAS(G12D)-mutated CRC to the recently discovered KRAS(G12D) inhibitor MRTX1133 h...

Descripción completa

Detalles Bibliográficos
Autores principales:	Feng, Juanjuan, Hu, Zhongwei, Xia, Xinting, Liu, Xiaogu, Lian, Zhengke, Wang, Hui, Wang, Liren, Wang, Cun, Zhang, Xueli, Pang, Xiufeng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10181928/ https://www.ncbi.nlm.nih.gov/pubmed/37020035 http://dx.doi.org/10.1038/s41388-023-02676-9

Ejemplares similares

KRAS(G12C)-independent feedback activation of wild-type RAS constrains KRAS(G12C) inhibitor efficacy
por: Ryan, Meagan B., et al.
Publicado: (2022)

Co-targeting KRAS G12C and EGFR reduces both mutant and wild-type RAS-GTP
por: McFall, Thomas, et al.
Publicado: (2022)

Differences in gynecologic tumor development in Amhr2-Cre mice with KRAS(G12D) or KRAS(G12V) mutations
por: Kun, Eucharist H. S., et al.
Publicado: (2020)

Computational Analysis of KRAS Mutations: Implications for Different Effects on the KRAS p.G12D and p.G13D Mutations
por: Chen, Chih-Chieh, et al.
Publicado: (2013)

KRAS(G12D) can be targeted by potent inhibitors via formation of salt bridge
por: Mao, Zhongwei, et al.
Publicado: (2022)

Kras(G12D) upregulates Notch signaling to induce gallbladder tumorigenesis in mice
por: Chung, Wen-Cheng, et al.
Publicado: (2017)

Role and regulation of Yap in KrasG12D-induced lung cancer
por: Mao, Yaopan, et al.
Publicado: (2017)

NUDT7 Loss Promotes Kras(G12D) CRC Development
por: Song, Jinsoo, et al.
Publicado: (2020)

Clinicopathologic Characteristics and Outcomes for Patients With KRAS G12D-Mutant NSCLC
por: Cooper, Alissa J., et al.
Publicado: (2022)

KRAS K104 modification affects the KRAS(G12D)-GEF interaction and mediates cell growth and motility
por: Chen, Chih-Chieh, et al.
Publicado: (2020)

Counteracting gemcitabine+nab-paclitaxel induced dysbiosis in KRAS wild type and KRAS(G12D) mutated pancreatic cancer in vivo model
por: Panebianco, Concetta, et al.
Publicado: (2023)

Kras(G12D) induces EGFR-MYC cross signaling in murine primary pancreatic ductal epithelial cells
por: Diersch, Sandra, et al.
Publicado: (2015)

Mechanisms of Resistance to KRAS(G12C) Inhibitors
por: Dunnett-Kane, Victoria, et al.
Publicado: (2021)

Gene expression deregulation by KRAS G12D and G12V in a BRAF V600E context
por: Monticone, Massimiliano, et al.
Publicado: (2008)

Detection of KRAS G12D in colorectal cancer stool by droplet digital PCR
por: Olmedillas-López, Susana, et al.
Publicado: (2017)

Differential Cell Susceptibilities to Kras(G12D) in the Setting of Obstructive Chronic Pancreatitis
por: Shi, Chanjuan, et al.
Publicado: (2019)

The Oxidative Drug Combination for Suppressing KRAS G12D Inducible Tumour Growth
por: Begimbetova, Dinara, et al.
Publicado: (2022)

Evaluation of KRAS(G12C) inhibitor responses in novel murine KRAS(G12C) lung cancer cell line models
por: Sisler, Daniel J., et al.
Publicado: (2023)

Molecular Characterization of Acquired Resistance to KRAS(G12C)–EGFR Inhibition in Colorectal Cancer
por: Yaeger, Rona, et al.
Publicado: (2023)

In silico-guided sequence modifications of K-ras epitopes improve immunological outcome against G12V and G13D mutant KRAS antigens
por: Ng, Allan Wee Ren, et al.
Publicado: (2018)

TEAD Inhibitors Sensitize KRAS(G12C) Inhibitors via Dual Cell Cycle Arrest in KRAS(G12C)-Mutant NSCLC
por: Tammaccaro, Salvina Laura, et al.
Publicado: (2023)

KRAS G12D mosaic mutation in a Chinese linear nevus sebaceous syndrome infant
por: Wang, Huijun, et al.
Publicado: (2015)

KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma
por: Bournet, Barbara, et al.
Publicado: (2016)

Oncogenic Kras(G12D) causes myeloproliferation via NLRP3 inflammasome activation
por: Hamarsheh, Shaima’a, et al.
Publicado: (2020)

Discovery of Prodrug of MRTX1133 as an Oral Therapy for Cancers with KRAS(G12D) Mutation
por: Ji, Xiang, et al.
Publicado: (2023)

KRAS G12D targeted therapies for pancreatic cancer: Has the fortress been conquered?
por: Bannoura, Sahar F., et al.
Publicado: (2022)

Dual Inhibition of KRAS(G12D) and Pan-ERBB Is Synergistic in Pancreatic Ductal Adenocarcinoma
por: Gulay, Kevin Christian Montecillo, et al.
Publicado: (2023)

Targeting KRAS G12C mutations in colorectal cancer
por: Zhao, Ming-He, et al.
Publicado: (2022)

α-Mangostin-encapsulated PLGA nanoparticles inhibit pancreatic carcinogenesis by targeting cancer stem cells in human, and transgenic (Kras(G12D), and Kras(G12D)/tp53R270H) mice
por: Verma, Raj Kumar, et al.
Publicado: (2016)

BMP4 and PHLDA1 are plausible drug-targetable candidate genes for KRAS G12A-, G12D-, and G12V-driven colorectal cancer
por: Ohnami, Shumpei, et al.
Publicado: (2021)

Suppression of mutant Kirsten-RAS (KRAS(G12D))-driven pancreatic carcinogenesis by dual-specificity MAP kinase phosphatases 5 and 6
por: Kidger, Andrew M., et al.
Publicado: (2022)

Bcl-xL Is a Key Mediator of Apoptosis Following KRAS(G12C) Inhibition in KRAS(G12C)-mutant Colorectal Cancer
por: Khawaja, Hajrah, et al.
Publicado: (2023)

Oncogenic KRAS G12D mutation promotes dimerization through a second, phosphatidylserine–dependent interface: a model for KRAS oligomerization
por: Lee, Ki-Young, et al.
Publicado: (2021)

Targeting KRAS in Lung Cancer Beyond KRAS G12C Inhibitors: The Immune Regulatory Role of KRAS and Novel Therapeutic Strategies
por: Cucurull, Marc, et al.
Publicado: (2022)

Optimisation of an Electrochemical DNA Sensor for Measuring KRAS G12D and G13D Point Mutations in Different Tumour Types †
por: Attoye, Bukola, et al.
Publicado: (2021)

Concomitant Mutations G12D and G13D on the Exon 2 of the KRAS Gene: Two Cases of Women with Colon Adenocarcinoma
por: De Falco, Elena, et al.
Publicado: (2021)

Discovery of potent and noncovalent KRAS(G12D) inhibitors: Structure-based virtual screening and biological evaluation
por: Wang, Yuting, et al.
Publicado: (2022)

Inactivation of TIF1γ Cooperates with Kras(G12D) to Induce Cystic Tumors of the Pancreas
por: Vincent, David F., et al.
Publicado: (2009)

CXCR2 signaling regulates KRAS((G12D))-induced autocrine growth of pancreatic cancer
por: Purohit, Abhilasha, et al.
Publicado: (2016)

Identification of New KRAS G12D Inhibitors through Computer-Aided Drug Discovery Methods
por: Kulkarni, Apoorva M., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_gq6pubc03ollr9q1rer42ln2ep